Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study)
Table 2
Baseline characteristics of subjects for long-term analysis set.
Demographics
Imidafenacin
Solifenacin
P-value
Subjects
11
14
Age (years)
(Mean ± SD)
<60, n (%)
0 (0%)
0 (0%)
≥60, n (%)
4 (36.4%)
4 (28.6%)
≥70, n (%)
7 (63.6%)
10 (71.4%)
Gender
Male, n (%)
7 (63.6%)
10 (71.4%)
Female, n (%)
4 (36.4%)
4 (28.6%)
OABSS (total score)
(Mean ± SD)
Siverity of OABSS
Mild, n (%)
0 (0%)
3 (21.4%)
Moderate, n (%)
11 (100%)
10 (71.4%)
Severe, n (%)
0 (0%)
1 (7.1%)
Postvoid residual volume (mL)
(Mean ± SD)
Each urination volume (mL)
(Mean ± SD)
Urination time (second)
(Mean ± SD)
Qmax (mL/s)
(Mean ± SD)
In male
Prostate volume (mL)
(Mean ± SD)
Use of α1 blocker, n (%)
6 (85.7%)
9 (90.0%)
Severity of OAB was defined as total OABSS score ≤5: mild; 6 to ≤11: moderate; ≥12: severe a: Unpaired t-test, b: Fisher’s exact test, c: Mann-Whitney U test, two-sided. SD: standard deviation.